Instead of following a traditional, slower Phase 1/2/3 trial structure, eGenesis leveraged the FDA's Expanded Access (compassionate use) pathway for its initial human cases. This strategy allowed for rapid learning from real-world patients, putting them two years ahead of schedule.

Ovelle plans to introduce its revolutionary in vitro gametogenesis (IVG) technology by initially focusing on patients for whom traditional IVF is not an option, such as cancer survivors. This builds a user base and proves the technology's safety and efficacy before targeting the broader, more cautious IVF market.

To increase the predictive power of their data, Aphaia structured its Phase 2 study to mimic a Phase 3 trial. By imposing minimal constraints on patients (e.g., no coaching or calorie restrictions), the results are more likely to reflect real-world outcomes. This reduces the risk of a performance drop-off between phases, making the asset more attractive to potential partners.

Don't wait until Phase 3 to think about commercialization. Biotech firms must embed secondary endpoints in Phase 2 trials that capture quality of life and patient journey insights. This data is critical for building a compelling value proposition that resonates with payers and secures market access.

While most focus on AI for drug discovery, Recursion is building an AI stack for clinical development, where 70% of costs lie. By using real-world data to pinpoint patient locations and causal AI to predict responders, they are improving trial enrollment rates by 1.5x. This demonstrates a holistic, end-to-end AI strategy that addresses bottlenecks across the entire value chain, not just the initial stages.

In rare diseases with small patient pools, recruiting for clinical trials is a major challenge. Effion Health's highly sensitive digital biomarkers can detect therapeutic efficacy with fewer participants, potentially reducing the required number of patients by 30%, which saves significant time and money for pharmaceutical companies.

Despite FDA readiness for a final Phase 3 trial, Connect Biopharma chose to run more Phase 2 studies. They discovered their long-term asthma drug worked in hours, not weeks, and are now pivoting to prove its value in acute, emergency situations, which informs a stronger, more targeted Phase 3 design.

Biotech leaders must stop viewing commercialization as a post-approval task. The critical window is Phase 2 clinical trials. By embedding patient journey and quality of life insights into secondary endpoints, companies can build a compelling value proposition for payers and physicians. Waiting until Phase 3 is too late.

Acadia's R&D process starts by considering what will ultimately matter to patients, physicians, and payers. This "end in mind" approach ensures clinical trials are designed to demonstrate meaningful, commercially relevant benefits. It forces realism about a drug's potential impact early in development, avoiding wasted resources on therapies that won't be adopted.